Cogent Biosciences, Inc.
Positive clinical trial results for bezuclastinib announced.
1 source·08/12, 21:08·sec.gov
Cogent Biosciences issues $230 million convertible notes.
1 source·18/11, 21:12·sec.gov
Cogent Biosciences announces significant equity and notes offerings.
1 source·13/11, 11:10·sec.gov
Positive results from bezuclastinib Phase 3 trial.
1 source·10/11, 13:02·sec.gov
10-Q form submitted!
1 source·07/11, 21:11·sec.gov
Cogent Biosciences announces Q3 2025 financial results.
1 source·03/11, 14:14·sec.gov
Cogent leases new headquarters office space in Waltham.
1 source·11/09, 20:32·sec.gov
Procedural announcement of financial results filing.
1 source·05/08, 12:44·sec.gov
Company raises $230 million in stock offering.
1 source·10/07, 12:02·sec.gov
Positive SUMMIT trial results for bezuclastinib announced.
1 source·07/07, 11:16·sec.gov
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
·finviz.com·29/05, 12:16
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now
·finviz.com·13/05, 12:53
Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
·finviz.com·05/05, 11:59